查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813825

美國荷爾蒙療法（零售）市場規模、佔有率和趨勢分析報告：按產品、適應症、給藥途徑、分銷管道和細分市場預測，2025-2033 年

U.S. Hormone Therapy (Retail Side) Market Size, Share & Trends Analysis Report By Product (Sex Hormones, Thyroid Hormones), By Indication, By Route of Administration (Oral, Parenteral), By Distribution Channel, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

市場規模與趨勢：

預計 2024 年美國荷爾蒙療法（零售）市場規模為 116.3 億美元，到 2033 年將達到 192.2 億美元，2025 年至 2033 年的複合年成長率為 5.83%。

這種成長是由人口老化和荷爾蒙失調盛行率上升所推動的，同時口服藥丸、經皮吸收貼片、皮下丸劑和注射劑等給藥技術的進步也提高了療效、便利性和依從性。

此外，藥局還提供便利的配藥和諮詢服務，Ro、Noom 和 Midi Health 等平台則將遠端醫療、線上處方和荷爾蒙送貨上門服務捆綁在一起，其中一些還結合了 GLP-1減重療法，以推動銷售。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場趨勢與展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 法律規範
  • 商業環境分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
  • 線上線下通路定價分析
  • 消費者對荷爾蒙療法的認知趨勢
  • 直接面對消費者 (DTC)經營模式的影響

第4章 產品業務分析

  • 美國荷爾蒙療法（零售）市場：產品差異分析
  • 美國荷爾蒙療法（零售）市場：產品細分儀表板
  • 2024 年和 2033 年產品趨勢和市佔率分析
  • 按產品
  • 性荷爾蒙
    • 性荷爾蒙市場，2021-2033
    • 雌激素替代療法（ERT）
    • 睾酮替代療法（TRT）
    • 黃體素治療
    • 合併荷爾蒙療法
  • 甲狀腺激素
  • 生長激素
  • 腎上腺激素
  • 其他荷爾蒙

第5章 指示業務分析

  • 美國荷爾蒙療法（零售）市場：適應症變化分析
  • 美國荷爾蒙療法（零售）市場：適應症細分儀表板
  • 2024 年和 2033 年適應症趨勢和市場佔有率分析
  • 按指示
  • 管理更年期和男性更年期
  • 甲狀腺機能低下症
  • 性腺功能低下
  • 生長激素缺乏症
  • 性別肯定療法
  • 不孕不育治療
  • 化妝品應用
  • 其他適應症

第6章 管理路線業務分析

  • 美國荷爾蒙療法（零售）市場：給藥途徑變化分析
  • 美國荷爾蒙療法（零售端）市場：給藥途徑細分儀表板
  • 2024 年和 2033 年給藥途徑趨勢和市佔率分析
  • 依給藥途徑
  • 口服
  • 腸外
  • 經皮
  • 其他給藥途徑

第7章通路業務分析

  • 美國荷爾蒙療法（零售）市場：分銷通路波動分析
  • 美國荷爾蒙療法（零售）市場：分銷通路細分儀表板
  • 2024年及2033年通路趨勢與市佔率分析
  • 按分銷管道
  • 線下藥局
    • 大型連鎖店
    • 獨立藥房
  • 網路藥局/遠端醫療
    • 純網路藥局
    • 獨立藥房
  • 遠端醫療和基於訂閱的DTC品牌

第8章 競爭態勢

  • 公司分類（線下藥局）
  • 公司分類（網路藥局）
  • 公司分類（荷爾蒙診所）
  • 參與企業概況
    • Offline Pharmacies
    • Online Pharmacies
    • Specialized Hormone Clinics
  • 企業市場分析
  • 戰略地圖
    • 區域擴張
    • 併購
    • 其他
  • 公司簡介/上市公司
  • Offline Pharmacies
    • CVS Health
    • Walgreens Boots Alliance, Inc.
    • Walmart Pharmacy
    • Rite Aid Corp
    • The Kroger Co.
    • Albertsons
    • Publix
    • Costco Wholesale Corporation
    • Meijer, Inc.
  • Online Pharmacies
    • Hims &Hers Health, Inc
    • CVS Health
    • Ro (Roman Health Ventures Inc.)
    • Lemonaid Health, Inc.
    • Mark Cuban Cost Plus Drug Company, PBC
    • Amazon.com, Inc.
    • Blink Health Administration LLC, Inc.
    • GoodRx, Inc
    • Honeybee Health Inc.
    • TruePill
    • NURX Inc.
    • AgelessRx
  • Specialized Hormone Clinics
    • Hims &Hers Health, Inc
    • BodyLogicMD
    • Defy Medical
    • Renew Vitality
    • Victory Men's Health
    • Hone Health
    • Joi & Blokes
    • Ways2Well
    • Honeybee Health Inc.
    • 4Ever Young Anti-aging Solutions
    • T CLINICS USA
Product Code: GVR-4-68040-700-4

Market Size & Trends:

The U.S. hormone therapy (retail side) market size was estimated at USD 11.63 billion in 2024 and is projected to reach USD 19.22 billion by 2033, growing at a CAGR of 5.83% from 2025 to 2033. This growth is driven by an increasing aging population and rising hormonal disorder prevalence. In addition, advances in delivery technologies, including oral pills, transdermal patches, subcutaneous pellets, and injectables, have enhanced efficacy, convenience, and adherence.

Moreover, the pharmacies now offer convenient dispensing and counseling, and platforms such as Ro, Noom, and Midi Health bundle telemedicine, online prescribing, and at-home delivery of hormones, with some combining GLP-1 weight-loss treatments, driving sales upward.

U.S. Hormone Therapy (Retail Side) Market Report Segmentation

This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. hormone therapy (retail side) market report based on product, indication, route of administration, and distribution channel:

  • Product Outlook (Revenue, USD Billion, 2021 - 2033)
  • Sex Hormones
    • Estrogen Replacement Therapy (ERT)
    • Testosterone Replacement Therapy (TRT)
    • Progesterone Therapy
    • Combined Hormone Therapy
  • Thyroid Hormones
  • Growth Hormones
  • Adrenal Hormones
  • Other Hormones
  • Indication Outlook (Revenue, USD Billion, 2021 - 2033)
  • Menopause & Andropause Management
  • Hypothyroidism
  • Hypogonadism
  • Growth Hormone Deficiency
  • Gender Affirming Therapy
  • Fertility Treatment
  • Cosmetic Applications
  • Other Indications
  • Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
  • Oral
  • Parenteral
  • Transdermal
  • Other Route of Administration
  • Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
  • Offline Retail Pharmacies
    • Large chains
    • Independent pharmacies
  • Online Pharmacies / Telehealth
    • Pure-play online pharmacies
    • Telehealth & subscription-based DTC brands
  • Others (Specialized Hormone Clinics)

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
  • 1.2. Estimates and Forecast Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
    • 1.4.5. Details of Primary Research
    • 1.4.6. Research Assumption
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Data Visualization
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. Objectives
    • 1.8.1. Objective - 1
    • 1.8.2. Objective - 2
    • 1.8.3. Objective - 3
  • 1.9. List of Secondary Sources
  • 1.10. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. U.S. Hormone Therapy (Retail Side) Market
    • 2.1.1. Market Snapshot
    • 2.1.2. Segment Snapshot
      • 2.1.2.1. Product & indication segment outlook
      • 2.1.2.2. Route of administration & distribution channel segment outlook
    • 2.1.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Regulatory Framework
  • 3.5. Business Environment Analysis Tools
    • 3.5.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrants
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
  • 3.6. Pricing Analysis in Online vs. Offline Channels
  • 3.7. Consumer Awareness Trends for Hormone Therapy
  • 3.8. Direct-to-Consumer (DTC) Business Models Impact

Chapter 4. Product Business Analysis

  • 4.1. U.S. Hormone Therapy (Retail Side) Market: Product Movement Analysis
  • 4.2. U.S. Hormone Therapy (Retail Side) Market: Product Segment Dashboard
  • 4.3. Product Movement & Market Share Analysis, 2024 & 2033
  • 4.4. U.S. Hormone Therapy (Retail Side) Market Estimates & Forecast, by Product
  • 4.5. Sex Hormones
    • 4.5.1. Sex Hormones Market, 2021 - 2033 (USD Million)
    • 4.5.2. Estrogen Replacement Therapy (ERT)
      • 4.5.2.1. Estrogen Replacement Therapy (ERT) market, 2021 - 2033 (USD Million)
    • 4.5.3. Testosterone Replacement Therapy (TRT)
      • 4.5.3.1. Testosterone Replacement Therapy (TRT) market, 2021 - 2033 (USD Million)
    • 4.5.4. Progesterone Therapy
      • 4.5.4.1. Progesterone therapy market, 2021 - 2033 (USD Million)
    • 4.5.5. Combined Hormone Therapy
      • 4.5.5.1. Combined hormone therapy market, 2021 - 2033 (USD Million)
  • 4.6. Thyroid Hormones
    • 4.6.1. Thyroid Hormones Market, 2021 - 2033 (USD Million)
  • 4.7. Growth Hormones
    • 4.7.1. Growth Hormones Market, 2021 - 2033 (USD Million)
  • 4.8. Adrenal Hormones
    • 4.8.1. Adrenal Hormones Market, 2021 - 2033 (USD Million)
  • 4.9. Other Hormones
    • 4.9.1. Other Hormones Market, 2021 - 2033 (USD Million)

Chapter 5. Indication Business Analysis

  • 5.1. U.S. Hormone Therapy (Retail Side) Market: Indication Movement Analysis
  • 5.2. U.S. Hormone Therapy (Retail Side) Market: Indication Segment Dashboard
  • 5.3. Indication Movement & Market Share Analysis, 2024 & 2033
  • 5.4. U.S. Hormone Therapy (Retail Side) Market Estimates & Forecast, by Indication
  • 5.5. Menopause & Andropause Management
    • 5.5.1. Menopause & Andropause Management Market, 2021 - 2033 (USD Million)
  • 5.6. Hypothyroidism
    • 5.6.1. Hypothyroidism Market, 2021 - 2033 (USD Million)
  • 5.7. Hypogonadism
    • 5.7.1. Hypogonadism Market, 2021 - 2033 (USD Million)
  • 5.8. Growth Hormone Deficiency
    • 5.8.1. Growth Hormone Deficiency Market, 2021 - 2033 (USD Million)
  • 5.9. Gender Affirming Therapy
    • 5.9.1. Gender Affirming Therapy Market, 2021 - 2033 (USD Million)
  • 5.10. Fertility Treatment
    • 5.10.1. Fertility Treatment Market, 2021 - 2033 (USD Million)
  • 5.11. Cosmetic Applications
    • 5.11.1. Cosmetic Applications Market, 2021 - 2033 (USD Million)
  • 5.12. Other Indications
    • 5.12.1. Other Indications Market, 2021 - 2033 (USD Million)

Chapter 6. Route of Administration Business Analysis

  • 6.1. U.S. Hormone Therapy (Retail Side) Market: Route of Administration Movement Analysis
  • 6.2. U.S. Hormone Therapy (Retail Side) Market: Route of Administration Segment Dashboard
  • 6.3. Route of Administration Movement & Market Share Analysis, 2024 & 2033
  • 6.4. U.S. Hormone Therapy (Retail Side) Market Estimates & Forecast, by Route of Administration
  • 6.5. Oral
    • 6.5.1. Oral Market, 2021 - 2033 (USD Million)
  • 6.6. Parenteral
    • 6.6.1. Parenteral Market, 2021 - 2033 (USD Million)
  • 6.7. Transdermal
    • 6.7.1. Transdermal Market, 2021 - 2033 (USD Million)
  • 6.8. Other Route of Administration
    • 6.8.1. Other Route of Administration Market, 2021 - 2033 (USD Million)

Chapter 7. Distribution Channel Business Analysis

  • 7.1. U.S. Hormone Therapy (Retail Side) Market: Distribution Channel Movement Analysis
  • 7.2. U.S. Hormone Therapy (Retail Side) Market: Distribution Channel Segment Dashboard
  • 7.3. Distribution Channel Movement & Market Share Analysis, 2024 & 2033
  • 7.4. U.S. Hormone Therapy (Retail Side) Market Estimates & Forecast, by Distribution Channel
  • 7.5. Offline Retail Pharmacies
    • 7.5.1. Offline Retail Pharmacies Market, 2021 - 2033 (USD Million)
    • 7.5.2. Large Chains
      • 7.5.2.1. Large chains market, 2021 - 2033 (USD Million)
    • 7.5.3. Independent Pharmacies
      • 7.5.3.1. Independent pharmacies market, 2021 - 2033 (USD Million)
  • 7.6. Online Pharmacies / Telehealth
    • 7.6.1. Online Pharmacies / Telehealth Market, 2021 - 2033 (USD Million)
    • 7.6.2. Pure-Play Online Pharmacies
      • 7.6.2.1. Pure-play online pharmacies market, 2021 - 2033 (USD Million)
    • 7.6.3. Independent Pharmacies
      • 7.6.3.1. Independent pharmacies market, 2021 - 2033 (USD Million)
  • 7.7. Telehealth & subscription-based DTC brands
    • 7.7.1. Telehealth & subscription-based DTC brands Market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization (Offline Pharmacies)
  • 8.2. Company Categorization (Online Pharmacies)
  • 8.3. Company Categorization (Specialized Hormone Clinics)
  • 8.4. Participant's Overview
    • 8.4.1. Offline Pharmacies
    • 8.4.2. Online Pharmacies
    • 8.4.3. Specialized Hormone Clinics
  • 8.5. Company Market Position Analysis
  • 8.6. Strategy Mapping
    • 8.6.1. Regional Expansion
    • 8.6.2. Mergers & Acquisitions
    • 8.6.3. Others
  • 8.7. Company Profiles/Listing
  • 8.8. Offline Pharmacies
    • 8.8.1. CVS Health
      • 8.8.1.1. Overview
      • 8.8.1.2. Financial performance
      • 8.8.1.3. Product benchmarking
      • 8.8.1.4. Strategic initiatives
    • 8.8.2. Walgreens Boots Alliance, Inc.
      • 8.8.2.1. Overview
      • 8.8.2.2. Financial performance
      • 8.8.2.3. Product benchmarking
      • 8.8.2.4. Strategic initiatives
    • 8.8.3. Walmart Pharmacy
      • 8.8.3.1. Overview
      • 8.8.3.2. Financial performance
      • 8.8.3.3. Product benchmarking
      • 8.8.3.4. Strategic initiatives
    • 8.8.4. Rite Aid Corp
      • 8.8.4.1. Overview
      • 8.8.4.2. Financial performance
      • 8.8.4.3. Product benchmarking
      • 8.8.4.4. Strategic initiatives
    • 8.8.5. The Kroger Co.
      • 8.8.5.1. Overview
      • 8.8.5.2. Financial performance
      • 8.8.5.3. Product benchmarking
      • 8.8.5.4. Strategic initiatives
    • 8.8.6. Albertsons
      • 8.8.6.1. Overview
      • 8.8.6.2. Financial performance
      • 8.8.6.3. Product benchmarking
      • 8.8.6.4. Strategic initiatives
    • 8.8.7. Publix
      • 8.8.7.1. Overview
      • 8.8.7.2. Financial performance
      • 8.8.7.3. Product benchmarking
      • 8.8.7.4. Strategic initiatives
    • 8.8.8. Costco Wholesale Corporation
      • 8.8.8.1. Overview
      • 8.8.8.2. Financial performance
      • 8.8.8.3. Product benchmarking
      • 8.8.8.4. Strategic initiatives
    • 8.8.9. Meijer, Inc.
      • 8.8.9.1. Overview
      • 8.8.9.2. Financial performance
      • 8.8.9.3. Product benchmarking
      • 8.8.9.4. Strategic initiatives
  • 8.9. Online Pharmacies
  • 8.10. Hims & Hers Health, Inc
    • 8.10.1. CVS Health
      • 8.10.1.1. Overview
      • 8.10.1.2. Financial performance
      • 8.10.1.3. Product benchmarking
      • 8.10.1.4. Strategic initiatives
    • 8.10.2. Ro (Roman Health Ventures Inc.)
      • 8.10.2.1. Overview
      • 8.10.2.2. Financial performance
      • 8.10.2.3. Product benchmarking
      • 8.10.2.4. Strategic initiatives
    • 8.10.3. Lemonaid Health, Inc.
      • 8.10.3.1. Overview
      • 8.10.3.2. Financial performance
      • 8.10.3.3. Product benchmarking
      • 8.10.3.4. Strategic initiatives
    • 8.10.4. Mark Cuban Cost Plus Drug Company, PBC
      • 8.10.4.1. Overview
      • 8.10.4.2. Financial performance
      • 8.10.4.3. Product benchmarking
      • 8.10.4.4. Strategic initiatives
    • 8.10.5. Amazon.com, Inc.
      • 8.10.5.1. Overview
      • 8.10.5.2. Financial performance
      • 8.10.5.3. Product benchmarking
      • 8.10.5.4. Strategic initiatives
    • 8.10.6. Blink Health Administration LLC, Inc.
      • 8.10.6.1. Overview
      • 8.10.6.2. Financial performance
      • 8.10.6.3. Product benchmarking
      • 8.10.6.4. Strategic initiatives
    • 8.10.7. GoodRx, Inc
      • 8.10.7.1. Overview
      • 8.10.7.2. Financial performance
      • 8.10.7.3. Product benchmarking
      • 8.10.7.4. Strategic initiatives
    • 8.10.8. Honeybee Health Inc.
      • 8.10.8.1. Overview
      • 8.10.8.2. Financial performance
      • 8.10.8.3. Product benchmarking
      • 8.10.8.4. Strategic initiatives
    • 8.10.9. TruePill
      • 8.10.9.1. Overview
      • 8.10.9.2. Financial performance
      • 8.10.9.3. Product benchmarking
      • 8.10.9.4. Strategic initiatives
    • 8.10.10. NURX Inc.
      • 8.10.10.1. Overview
      • 8.10.10.2. Financial performance
      • 8.10.10.3. Product benchmarking
      • 8.10.10.4. Strategic initiatives
    • 8.10.11. AgelessRx
      • 8.10.11.1. Overview
      • 8.10.11.2. Financial performance
      • 8.10.11.3. Product benchmarking
      • 8.10.11.4. Strategic initiatives
  • 8.11. Specialized Hormone Clinics
  • 8.12. Hims & Hers Health, Inc
    • 8.12.1. BodyLogicMD
      • 8.12.1.1. Overview
      • 8.12.1.2. Financial performance
      • 8.12.1.3. Product benchmarking
      • 8.12.1.4. Strategic initiatives
    • 8.12.2. Defy Medical
      • 8.12.2.1. Overview
      • 8.12.2.2. Financial performance
      • 8.12.2.3. Product benchmarking
      • 8.12.2.4. Strategic initiatives
    • 8.12.3. Renew Vitality
      • 8.12.3.1. Overview
      • 8.12.3.2. Financial performance
      • 8.12.3.3. Product benchmarking
      • 8.12.3.4. Strategic initiatives
    • 8.12.4. Victory Men's Health
      • 8.12.4.1. Overview
      • 8.12.4.2. Financial performance
      • 8.12.4.3. Product benchmarking
      • 8.12.4.4. Strategic initiatives
    • 8.12.5. Hone Health
      • 8.12.5.1. Overview
      • 8.12.5.2. Financial performance
      • 8.12.5.3. Product benchmarking
      • 8.12.5.4. Strategic initiatives
    • 8.12.6. Joi & Blokes
      • 8.12.6.1. Overview
      • 8.12.6.2. Financial performance
      • 8.12.6.3. Product benchmarking
      • 8.12.6.4. Strategic initiatives
    • 8.12.7. Ways2Well
      • 8.12.7.1. Overview
      • 8.12.7.2. Financial performance
      • 8.12.7.3. Product benchmarking
      • 8.12.7.4. Strategic initiatives
    • 8.12.8. Honeybee Health Inc.
      • 8.12.8.1. Overview
      • 8.12.8.2. Financial performance
      • 8.12.8.3. Product benchmarking
      • 8.12.8.4. Strategic initiatives
    • 8.12.9. 4Ever Young Anti-aging Solutions
      • 8.12.9.1. Overview
      • 8.12.9.2. Financial performance
      • 8.12.9.3. Product benchmarking
      • 8.12.9.4. Strategic initiatives
    • 8.12.10. T CLINICS USA
      • 8.12.10.1. Overview
      • 8.12.10.2. Financial performance
      • 8.12.10.3. Product benchmarking
      • 8.12.10.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. hormone therapy (Retail Side) market, by product, 2021 - 2033 (USD Million)
  • Table 4 U.S. Hormone Therapy (Retail Side) Market: Strategy Mapping by Product
  • Table 5 U.S. hormone therapy (Retail Side) market, by indication, 2021 - 2033 (USD Million)
  • Table 6 U.S. Hormone Therapy (Retail Side) Market: Product and Strategy Mapping by Indication
  • Table 7 U.S. hormone therapy (Retail Side) market, by route of administration, 2021 - 2033 (USD Million)
  • Table 8 U.S. Hormone Therapy (Retail Side) Market: Route of Administration and Strategy Mapping by Route of Administration
  • Table 9 U.S. hormone therapy (Retail Side) market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 10 U.S. Hormone Therapy (Retail Side) Market: Distribution Channel and Strategy Mapping by Route of Administration

List of Figures

  • Fig. 1 U.S. hormone therapy (Retail Side) market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment outlook
  • Fig. 10 Segment outlook
  • Fig. 11 Competitive landscape
  • Fig. 12 U.S. hormone therapy (Retail Side) market lineage outlook
  • Fig. 13 U.S. hormone therapy (Retail Side) market dynamics
  • Fig. 14 Market driver relevance analysis (Current & future impact)
  • Fig. 15 Market restraint relevance analysis (Current & future impact)
  • Fig. 16 U.S. hormone therapy (Retail Side) market: PESTLE analysis
  • Fig. 17 U.S. hormone therapy (Retail Side) market: Porter's five forces analysis
  • Fig. 18 U.S. hormone therapy (Retail Side) market: Product segment dashboard
  • Fig. 19 U.S. hormone therapy (Retail Side) market: Product market share analysis, 2024 & 2033
  • Fig. 20 Sex hormones market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 Estrogen Replacement Therapy (ERT) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Testosterone Replacement Therapy (TRT) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Progesterone therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Combined hormone therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Thyroid hormones market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Growth hormones market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Adrenal hormones market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Other hormones market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 U.S. hormone therapy (retail side) market: Indication outlook key takeaways
  • Fig. 30 U.S. Hormone Therapy (Retail Side) Market: Indication Movement Analysis (USD Million)
  • Fig. 31 Menopause & andropause management market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Hypothyroidism market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Hypogonadism market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Growth hormone deficiency market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Gender affirming therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Fertility treatment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Cosmetic applications market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 U.S. hormone therapy (retail side) market: Route of administration outlook key takeaways
  • Fig. 40 U.S. Hormone Therapy (Retail Side) Market: Route of Administration Movement Analysis (USD Million)
  • Fig. 41 Oral market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Parenteral market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Transdermal market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 U.S. hormone therapy (retail side) market: Distribution channel outlook key takeaways
  • Fig. 46 U.S. Hormone Therapy (Retail Side) Market: Distribution Channel Movement Analysis (USD Million)
  • Fig. 47 Offline retail pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Large chains market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Independent pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Online pharmacies / telehealth market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Pure-play online pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Telehealth & subscription-based DTC brands market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Others (specialized hormone clinics) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Competition categorization (Offline Pharmacies)
  • Fig. 55 Competition categorization (Online Pharmacies)
  • Fig. 56 Competition categorization (Specialized Hormone Clinics)
  • Fig. 57 Company market position analysis
  • Fig. 58 Company market position analysis
  • Fig. 59 Company market position analysis
  • Fig. 60 Strategy mapping